By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French firms Hybrigenics and Servier today announced a licensing and research deal targeting deubiquitinating enzymes, or DUBs, for various diseases that could result in the development of companion diagnostics.

Under the terms of the deal, Hybrigenics will identify and validate new targets among DUBs for cancer, diseases in neurology, psychiatry, rheumatology, and ophthalmology, as well as diabetes, and cardiovascular illness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.